Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Indaptus Therapeutics ( (INDP) ) has provided an announcement.
On January 20, 2026, Indaptus Therapeutics further amended the employment agreements of Co-Chief Executive Officer Jeffrey A. Meckler and Chief Science Officer Michael J. Newman, implementing a salary adjustment effective January 15, 2026 that sets each executive’s annual pay at $60,000 for the remainder of the year, signaling a significant compensation reduction that may reflect the company’s ongoing capital or cost-management efforts following its previously disclosed securities purchase agreement with investor David E. Lazar. Also on January 20, 2026, board member Anthony Maddaluna reversed his previously announced plan to resign at the next special meeting of stockholders, with the board accepting his decision to remain, thereby maintaining continuity in the company’s governance structure and preserving his roles on the Compensation and Nominating Committees.
The most recent analyst rating on (INDP) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.
Spark’s Take on INDP Stock
According to Spark, TipRanks’ AI Analyst, INDP is a Neutral.
The score is held down primarily by weak financial performance (no revenue, sustained losses, negative cash flow, and a reduced equity/asset base). Technicals offer only modest near-term support, while valuation is constrained by negative earnings and no dividend. A positive board appointment helps on governance but is secondary to the company’s financial risk profile.
To see Spark’s full report on INDP stock, click here.
More about Indaptus Therapeutics
Indaptus Therapeutics, Inc. is a biotechnology company focused on developing immunotherapy treatments, led by a Co-Chief Executive Officer and a Chief Science Officer and overseen by a board of directors and key committees such as the Compensation and Nominating Committees.
Average Trading Volume: 706,027
Technical Sentiment Signal: Sell
Current Market Cap: $7.43M
For an in-depth examination of INDP stock, go to TipRanks’ Overview page.